Work

Phase 1/2 study of oral rucaparib: Final phase 1 results.

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.2573

Authors: Rebecca Sophie Kristeleit, Howard A. Burris, Patricia LoRusso, Manish R. Patel, Uzma Saddia Asghar, Fatima El-Khouly, Alan Hilary Calvert, Jeffrey R. Infante, John Frederick Hilton, Sara M. Tolaney, Muaiad Kittaneh, Heidi Giordano, Jennifer Borrow, Sarah S. Jaw-Tsai, Geoffrey Shapiro

Institutions: University College London, Sarah Cannon, Tennessee Oncology, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Florida Cancer Specialists & Research Institute, University College Hospital, Dana-Farber Cancer Institute, Clovis Oncology (United States)

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W182695913

Cites:

Cited by: 27

Related to: 10